Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials

Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials

Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills treatment goals important to patients with PV including good quality of life, the slowing of disease progression, and long event-free surviva...

Full description

Bibliographic Details
Main Author: Heinz Gisslinger
Format: Article
Language:English
Published: Galenos Publishing House 2023-12-01
Series:Turkish Journal of Hematology
Subjects:
ph-negative chronic myeloproliferative neoplasm
chronic myeloproliferative neoplasms
neoplasia
hematopoietic stem and progenitor cells
hematopoiesis
pharmacotherapeutics
oncogenes
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-91455

Internet

https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-91455

Similar Items